Birlasoft Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3v9y2f8pux3twfq2c1vmretu.pdf

Key Takeaways


Demand Environment

Angan Guha: "Our client budgets have not gone down, but it is on a 'hold and wait' pattern."

Revenue Growth & Vertical Performance

VerticalTrendCommentary
Manufacturing▲ Strong reboundERP deferments from Q1 ramped up; up 4.7% QoQ.
E&U▲ Strong reboundUp 4.7% QoQ alongside Manufacturing.
BFSI▲ Continued strengthSeven straight quarters of growth; up 1.4% QoQ.
Digital & Data▲ ReboundUp 6.6% QoQ after prior-quarter pressure.
Life Sciences▼ WeakThree quarters of underperformance; soft for a couple more.
Healthcare▼ MutedProject-specific issues, not sector-wide; strong bounce-back expected.
Infra▼ Sequential dropBase effect after strong Q1; growth expected to resume.

Margins: The Decline and the Recovery Plan

Angan Guha: "Q3 will be a muted quarter from a margin standpoint, but Q4 onwards, you will see a clear margin improvement."

Deal Dynamics: Consolidation, Renewals, and the Pipeline

Angan Guha: "I am going to go after market share. I am going to win deals at slightly lower margins in the market. But if I am being able to balance that out... I am reasonably confident that I can win market share through the vendor consolidation deals."

People, Delivery & Operating Model


Predictability & Long-Term Positioning

Angan Guha: "Even in the future, will there be a couple of quarters where there will be a little bit of unpredictability? It will happen, because the markets are very volatile. But our job now going forward is to be very predictable over the next 6, 7, 8, 9 quarters so that investors like yourself also get a view on it."

Guidance & Commitments

CommitmentSpecificsTimeline
Margin trough and recoveryQ3 is absolute margin bottom due to 150 bps wage hike; Q4 onwards clear improvement every subsequent quarterQ3 FY25 trough; Q4 FY25 recovery start
Desired margin bandReturn to 15% to 16.5% rangeNo fixed date; "may take longer than expected"
Revenue growth trajectoryStrive for QoQ growth even in seasonally soft Q3; Q4 growth expectedQ3 and Q4 FY25
Quarterly TCV targetConsistently deliver $250 million per quarterQ4 FY25 is the target to attempt it; Q3 unlikely
Life Sciences recoveryVertical to return to growth after remaining soft"A couple of quarters"
Healthcare bounce-backStrong recovery expected from project-specific weakness"A couple of quarters"
Transformation deal conversionTransformation projects back on the table once U.S. election cycle endsRoughly six-month lag after election clarity
Annuity business disclosureProvide statistics on annuity vs. project-based revenue"In a couple of quarters"
PredictabilityAim to be "very predictable" for investorsOver the next 6 to 9 quarters

Key Metrics

MetricQ2 FY25
Revenue (USD)$163.3 million, +2.6% QoQ and +3.2% YoY
Revenue (INR)₹1,368 crore, +3.1% QoQ and +4.5% YoY
EBITDA$19.7 million, down from $23.4 million in Q1
EBITDA margin12.1%, down from 14.7% in Q1; Q1 included a one-time benefit of ₹22.2 crore
PAT$15.2 million (₹127.5 crore)
Effective tax rate24.9%; full-year ETR expected 25%–26%
Cash and bank balance$221.8 million, up 27.8% after $13 million dividend payout
Operating cash flow$12.9 million
Quarterly collections$176 million, highest in the last six quarters
DSO~58 days, up QoQ due to collections shifting into early October
Interim dividend₹2.50 per share
Top 5 accounts revenue contribution36.7% of total revenues, grew 3.9% QoQ
Top 10 accounts revenue contribution52.5% of total revenues, grew 2.4% QoQ
Top 20 accounts revenue contribution64.9% of total revenues, grew 2.3% QoQ
Manufacturing vertical growth+4.7% QoQ
Energy and Utilities vertical growth+4.7% QoQ
BFSI vertical growth+1.4% QoQ
ERP business growth+4.3% QoQ
Digital and Data business growth+6.6% QoQ
Onsite revenue ratio~51%, up from ~46%–48% in prior quarters
Half-year deal signings~$300 million, lower than prior year
Win ratio30%–32%; aspiration is 35%–38%
Net new and existing new deal mix~50% of order book
Voluntary attritionNot stated
Utilization+30 bps QoQ
Salary hike impact expected in Q3150 bps margin dent
Core services underlying growth~4.5% (per an analyst's math, adjusting for pass-through reduction)
Like-to-like EBITDA margin (excl. Q1 one-off)~13%–13.1% (per an analyst's math)
Operational margin contraction (excl. one-off)~100 bps (per an analyst's math)
U.S. revenue share86%–87% of total business
Vendor consolidation deal size range$10 million to $30 million
Target quarterly deal signings$250 million
FY24 TCV growth+1% YoY